Seeking Alpha

Arena Pharmaceutical (ARNA): Q3 EPS loss of -$0.07 beats by $0.02. Revenue of $1.5M (-57% Y/Y)...

Arena Pharmaceutical (ARNA): Q3 EPS loss of -$0.07 beats by $0.02. Revenue of $1.5M (-57% Y/Y) misses by $2M. Shares +1.71% AH. (PR)

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (6)
  • Darrellt
    , contributor
    Comments (83) | Send Message
     
    Sort of immaterial numbers given that the future and Belviq is where we have to evaluate this stock.
    6 Nov 2012, 04:22 PM Reply Like
  • bil
    , contributor
    Comments (64) | Send Message
     
    looks like a buyout is long gone
    6 Nov 2012, 04:47 PM Reply Like
  • Veltri
    , contributor
    Comments (3) | Send Message
     
    How can they have revenue, they have not yet gone to market?
    6 Nov 2012, 04:54 PM Reply Like
  • Veltri
    , contributor
    Comments (3) | Send Message
     
    How can there be any revenue when their product has not yet been to market?
    6 Nov 2012, 04:54 PM Reply Like
  • Charles U. Farley
    , contributor
    Comments (17) | Send Message
     
    I am so glad you posted that.....[!]
    6 Nov 2012, 05:53 PM Reply Like
  • targa86guy
    , contributor
    Comments (3) | Send Message
     
    Revenue comes from mile stone payments.
    This stock is going to rise based on a well planned, and executed launch.
    6 Nov 2012, 11:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs